Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Amphastar Pharmaceuticals’s reported figures.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
FAQ
- What is Amphastar Pharmaceuticals's EBITDA?
- Amphastar Pharmaceuticals (AMPH) reported EBITDA of $54.04M in Q2 2026.
- How has Amphastar Pharmaceuticals's EBITDA changed year-over-year?
- Amphastar Pharmaceuticals's EBITDA decreased by 4.9% year-over-year, from $56.8M to $54.04M.
- What is the long-term trend for Amphastar Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's EBITDA has grown at a 20.6% compound annual growth rate (CAGR), from $93.15M to $197.1M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Amphastar Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude